 | • レポートコード：MRC23Q38503 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の半固体投与剤市場について調査・分析し、世界の半固体投与剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（軟膏、ペースト、絆創膏、ジェル）、用途別セグメント分析（皮膚、鼻腔、膣腔、直腸腔、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Johnson & Johnson、Merck & Co、Bayer AG、Hisamitsu Pharmaceutical、Glenmark Pharmaceuticals、Cipla Ltd、Nestle SA、Novartis AG、GlaxoSmithKline plc、Bausch Health Companies、Allergan、Biofrontera、Crown Laboratories、Akorn、Ingenus Pharmaceuticals、Sun Pharmaceuticals、Crescita Therapeutics、Mylan N.V.、Encore Dermatology、LEO Pharma、Almirall, S.A、Aclaris Therapeutics、Taro Pharmaceutical Industries、Teligent Pharma、Perrigo Pharmaなどが含まれています。世界の半固体投与剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、半固体投与剤市場規模を推定する際に考慮しました。本レポートは、半固体投与剤の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、半固体投与剤に関するビジネス上の意思決定に役立てることを目的としています。 ・半固体投与剤市場の概要 - 製品の定義 - 半固体投与剤のタイプ別セグメント - 世界の半固体投与剤市場規模：タイプ別分析（軟膏、ペースト、絆創膏、ジェル） - 半固体投与剤の用途別セグメント - 世界の半固体投与剤市場規模：用途別分析（皮膚、鼻腔、膣腔、直腸腔、その他） - 世界の半固体投与剤市場規模予測（2018年-2029年） - 半固体投与剤の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - 半固体投与剤市場の競争状況およびトレンド ・半固体投与剤の地域別市場規模 - 北米の半固体投与剤市場規模（2018年-2029年） - アメリカの半固体投与剤市場規模（2018年-2029年） - ヨーロッパの半固体投与剤市場規模（2018年-2029年） - アジア太平洋の半固体投与剤市場規模（2018年-2029年） - 中国の半固体投与剤市場規模（2018年-2029年） - 日本の半固体投与剤市場規模（2018年-2029年） - 韓国の半固体投与剤市場規模（2018年-2029年） - インドの半固体投与剤市場規模（2018年-2029年） - オーストラリアの半固体投与剤市場規模（2018年-2029年） - 中南米の半固体投与剤市場規模（2018年-2029年） - 中東・アフリカの半固体投与剤市場規模（2018年-2029年） ・タイプ別セグメント：軟膏、ペースト、絆創膏、ジェル - 世界の半固体投与剤のタイプ別販売量（2018年-2023年） - 世界の半固体投与剤のタイプ別売上（2018年-2023年） - 世界の半固体投与剤のタイプ別価格 ・用途別セグメント：皮膚、鼻腔、膣腔、直腸腔、その他 - 世界の半固体投与剤の用途別販売量（2018年-2023年） - 世界の半固体投与剤の用途別売上（2018年-2023年） - 世界の半固体投与剤の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Johnson & Johnson、Merck & Co、Bayer AG、Hisamitsu Pharmaceutical、Glenmark Pharmaceuticals、Cipla Ltd、Nestle SA、Novartis AG、GlaxoSmithKline plc、Bausch Health Companies、Allergan、Biofrontera、Crown Laboratories、Akorn、Ingenus Pharmaceuticals、Sun Pharmaceuticals、Crescita Therapeutics、Mylan N.V.、Encore Dermatology、LEO Pharma、Almirall, S.A、Aclaris Therapeutics、Taro Pharmaceutical Industries、Teligent Pharma、Perrigo Pharma ・産業チェーンと販売チャネルの分析 - 半固体投与剤産業チェーン分析 - 半固体投与剤の主要原材料 - 半固体投与剤の販売チャネル - 半固体投与剤のディストリビューター - 半固体投与剤の主要顧客 ・半固体投与剤市場ダイナミクス - 半固体投与剤の業界動向 - 半固体投与剤市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Semi-solid Dosage market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Semi-solid Dosage is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Semi-solid Dosage is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Semi-solid Dosage include Johnson & Johnson, Merck & Co, Bayer AG, Hisamitsu Pharmaceutical, Glenmark Pharmaceuticals, Cipla Ltd, Nestle SA, Novartis AG and GlaxoSmithKline plc, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Semi-solid Dosage, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Semi-solid Dosage.
The Semi-solid Dosage market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Semi-solid Dosage market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Semi-solid Dosage manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Johnson & Johnson
Merck & Co
Bayer AG
Hisamitsu Pharmaceutical
Glenmark Pharmaceuticals
Cipla Ltd
Nestle SA
Novartis AG
GlaxoSmithKline plc
Bausch Health Companies
Allergan
Biofrontera
Crown Laboratories
Akorn
Ingenus Pharmaceuticals
Sun Pharmaceuticals
Crescita Therapeutics
Mylan N.V.
Encore Dermatology
LEO Pharma
Almirall, S.A
Aclaris Therapeutics
Taro Pharmaceutical Industries
Teligent Pharma
Perrigo Pharma
Segment by Type
Ointment
Paste
Plaster
Gel
Segment by Application
Skin
Nasal Cavity
Vaginal Cavity
Rectal Cavity
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Semi-solid Dosage manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Semi-solid Dosage in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Semi-solid Dosage Market Overview
1.1 Product Overview and Scope of Semi-solid Dosage
1.2 Semi-solid Dosage Segment by Type
1.2.1 Global Semi-solid Dosage Market Value Comparison by Type (2023-2029)
1.2.2 Ointment
1.2.3 Paste
1.2.4 Plaster
1.2.5 Gel
1.3 Semi-solid Dosage Segment by Application
1.3.1 Global Semi-solid Dosage Market Value by Application: (2023-2029)
1.3.2 Skin
1.3.3 Nasal Cavity
1.3.4 Vaginal Cavity
1.3.5 Rectal Cavity
1.3.6 Other
1.4 Global Semi-solid Dosage Market Size Estimates and Forecasts
1.4.1 Global Semi-solid Dosage Revenue 2018-2029
1.4.2 Global Semi-solid Dosage Sales 2018-2029
1.4.3 Global Semi-solid Dosage Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Semi-solid Dosage Market Competition by Manufacturers
2.1 Global Semi-solid Dosage Sales Market Share by Manufacturers (2018-2023)
2.2 Global Semi-solid Dosage Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Semi-solid Dosage Average Price by Manufacturers (2018-2023)
2.4 Global Semi-solid Dosage Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Semi-solid Dosage, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Semi-solid Dosage, Product Type & Application
2.7 Semi-solid Dosage Market Competitive Situation and Trends
2.7.1 Semi-solid Dosage Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Semi-solid Dosage Players Market Share by Revenue
2.7.3 Global Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Semi-solid Dosage Retrospective Market Scenario by Region
3.1 Global Semi-solid Dosage Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Semi-solid Dosage Global Semi-solid Dosage Sales by Region: 2018-2029
3.2.1 Global Semi-solid Dosage Sales by Region: 2018-2023
3.2.2 Global Semi-solid Dosage Sales by Region: 2024-2029
3.3 Global Semi-solid Dosage Global Semi-solid Dosage Revenue by Region: 2018-2029
3.3.1 Global Semi-solid Dosage Revenue by Region: 2018-2023
3.3.2 Global Semi-solid Dosage Revenue by Region: 2024-2029
3.4 North America Semi-solid Dosage Market Facts & Figures by Country
3.4.1 North America Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Semi-solid Dosage Sales by Country (2018-2029)
3.4.3 North America Semi-solid Dosage Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Semi-solid Dosage Market Facts & Figures by Country
3.5.1 Europe Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Semi-solid Dosage Sales by Country (2018-2029)
3.5.3 Europe Semi-solid Dosage Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Semi-solid Dosage Market Facts & Figures by Country
3.6.1 Asia Pacific Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Semi-solid Dosage Sales by Country (2018-2029)
3.6.3 Asia Pacific Semi-solid Dosage Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Semi-solid Dosage Market Facts & Figures by Country
3.7.1 Latin America Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Semi-solid Dosage Sales by Country (2018-2029)
3.7.3 Latin America Semi-solid Dosage Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Semi-solid Dosage Market Facts & Figures by Country
3.8.1 Middle East and Africa Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Semi-solid Dosage Sales by Country (2018-2029)
3.8.3 Middle East and Africa Semi-solid Dosage Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Semi-solid Dosage Sales by Type (2018-2029)
4.1.1 Global Semi-solid Dosage Sales by Type (2018-2023)
4.1.2 Global Semi-solid Dosage Sales by Type (2024-2029)
4.1.3 Global Semi-solid Dosage Sales Market Share by Type (2018-2029)
4.2 Global Semi-solid Dosage Revenue by Type (2018-2029)
4.2.1 Global Semi-solid Dosage Revenue by Type (2018-2023)
4.2.2 Global Semi-solid Dosage Revenue by Type (2024-2029)
4.2.3 Global Semi-solid Dosage Revenue Market Share by Type (2018-2029)
4.3 Global Semi-solid Dosage Price by Type (2018-2029)
5 Segment by Application
5.1 Global Semi-solid Dosage Sales by Application (2018-2029)
5.1.1 Global Semi-solid Dosage Sales by Application (2018-2023)
5.1.2 Global Semi-solid Dosage Sales by Application (2024-2029)
5.1.3 Global Semi-solid Dosage Sales Market Share by Application (2018-2029)
5.2 Global Semi-solid Dosage Revenue by Application (2018-2029)
5.2.1 Global Semi-solid Dosage Revenue by Application (2018-2023)
5.2.2 Global Semi-solid Dosage Revenue by Application (2024-2029)
5.2.3 Global Semi-solid Dosage Revenue Market Share by Application (2018-2029)
5.3 Global Semi-solid Dosage Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Johnson & Johnson Semi-solid Dosage Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Corporation Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co Semi-solid Dosage Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Bayer AG
6.3.1 Bayer AG Corporation Information
6.3.2 Bayer AG Description and Business Overview
6.3.3 Bayer AG Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bayer AG Semi-solid Dosage Product Portfolio
6.3.5 Bayer AG Recent Developments/Updates
6.4 Hisamitsu Pharmaceutical
6.4.1 Hisamitsu Pharmaceutical Corporation Information
6.4.2 Hisamitsu Pharmaceutical Description and Business Overview
6.4.3 Hisamitsu Pharmaceutical Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hisamitsu Pharmaceutical Semi-solid Dosage Product Portfolio
6.4.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.5 Glenmark Pharmaceuticals
6.5.1 Glenmark Pharmaceuticals Corporation Information
6.5.2 Glenmark Pharmaceuticals Description and Business Overview
6.5.3 Glenmark Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Glenmark Pharmaceuticals Semi-solid Dosage Product Portfolio
6.5.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.6 Cipla Ltd
6.6.1 Cipla Ltd Corporation Information
6.6.2 Cipla Ltd Description and Business Overview
6.6.3 Cipla Ltd Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Cipla Ltd Semi-solid Dosage Product Portfolio
6.6.5 Cipla Ltd Recent Developments/Updates
6.7 Nestle SA
6.6.1 Nestle SA Corporation Information
6.6.2 Nestle SA Description and Business Overview
6.6.3 Nestle SA Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Nestle SA Semi-solid Dosage Product Portfolio
6.7.5 Nestle SA Recent Developments/Updates
6.8 Novartis AG
6.8.1 Novartis AG Corporation Information
6.8.2 Novartis AG Description and Business Overview
6.8.3 Novartis AG Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Novartis AG Semi-solid Dosage Product Portfolio
6.8.5 Novartis AG Recent Developments/Updates
6.9 GlaxoSmithKline plc
6.9.1 GlaxoSmithKline plc Corporation Information
6.9.2 GlaxoSmithKline plc Description and Business Overview
6.9.3 GlaxoSmithKline plc Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GlaxoSmithKline plc Semi-solid Dosage Product Portfolio
6.9.5 GlaxoSmithKline plc Recent Developments/Updates
6.10 Bausch Health Companies
6.10.1 Bausch Health Companies Corporation Information
6.10.2 Bausch Health Companies Description and Business Overview
6.10.3 Bausch Health Companies Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bausch Health Companies Semi-solid Dosage Product Portfolio
6.10.5 Bausch Health Companies Recent Developments/Updates
6.11 Allergan
6.11.1 Allergan Corporation Information
6.11.2 Allergan Semi-solid Dosage Description and Business Overview
6.11.3 Allergan Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Allergan Semi-solid Dosage Product Portfolio
6.11.5 Allergan Recent Developments/Updates
6.12 Biofrontera
6.12.1 Biofrontera Corporation Information
6.12.2 Biofrontera Semi-solid Dosage Description and Business Overview
6.12.3 Biofrontera Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Biofrontera Semi-solid Dosage Product Portfolio
6.12.5 Biofrontera Recent Developments/Updates
6.13 Crown Laboratories
6.13.1 Crown Laboratories Corporation Information
6.13.2 Crown Laboratories Semi-solid Dosage Description and Business Overview
6.13.3 Crown Laboratories Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Crown Laboratories Semi-solid Dosage Product Portfolio
6.13.5 Crown Laboratories Recent Developments/Updates
6.14 Akorn
6.14.1 Akorn Corporation Information
6.14.2 Akorn Semi-solid Dosage Description and Business Overview
6.14.3 Akorn Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Akorn Semi-solid Dosage Product Portfolio
6.14.5 Akorn Recent Developments/Updates
6.15 Ingenus Pharmaceuticals
6.15.1 Ingenus Pharmaceuticals Corporation Information
6.15.2 Ingenus Pharmaceuticals Semi-solid Dosage Description and Business Overview
6.15.3 Ingenus Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Ingenus Pharmaceuticals Semi-solid Dosage Product Portfolio
6.15.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.16 Sun Pharmaceuticals
6.16.1 Sun Pharmaceuticals Corporation Information
6.16.2 Sun Pharmaceuticals Semi-solid Dosage Description and Business Overview
6.16.3 Sun Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sun Pharmaceuticals Semi-solid Dosage Product Portfolio
6.16.5 Sun Pharmaceuticals Recent Developments/Updates
6.17 Crescita Therapeutics
6.17.1 Crescita Therapeutics Corporation Information
6.17.2 Crescita Therapeutics Semi-solid Dosage Description and Business Overview
6.17.3 Crescita Therapeutics Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Crescita Therapeutics Semi-solid Dosage Product Portfolio
6.17.5 Crescita Therapeutics Recent Developments/Updates
6.18 Mylan N.V.
6.18.1 Mylan N.V. Corporation Information
6.18.2 Mylan N.V. Semi-solid Dosage Description and Business Overview
6.18.3 Mylan N.V. Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Mylan N.V. Semi-solid Dosage Product Portfolio
6.18.5 Mylan N.V. Recent Developments/Updates
6.19 Encore Dermatology
6.19.1 Encore Dermatology Corporation Information
6.19.2 Encore Dermatology Semi-solid Dosage Description and Business Overview
6.19.3 Encore Dermatology Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Encore Dermatology Semi-solid Dosage Product Portfolio
6.19.5 Encore Dermatology Recent Developments/Updates
6.20 LEO Pharma
6.20.1 LEO Pharma Corporation Information
6.20.2 LEO Pharma Semi-solid Dosage Description and Business Overview
6.20.3 LEO Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.20.4 LEO Pharma Semi-solid Dosage Product Portfolio
6.20.5 LEO Pharma Recent Developments/Updates
6.21 Almirall, S.A
6.21.1 Almirall, S.A Corporation Information
6.21.2 Almirall, S.A Semi-solid Dosage Description and Business Overview
6.21.3 Almirall, S.A Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Almirall, S.A Semi-solid Dosage Product Portfolio
6.21.5 Almirall, S.A Recent Developments/Updates
6.22 Aclaris Therapeutics
6.22.1 Aclaris Therapeutics Corporation Information
6.22.2 Aclaris Therapeutics Semi-solid Dosage Description and Business Overview
6.22.3 Aclaris Therapeutics Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Aclaris Therapeutics Semi-solid Dosage Product Portfolio
6.22.5 Aclaris Therapeutics Recent Developments/Updates
6.23 Taro Pharmaceutical Industries
6.23.1 Taro Pharmaceutical Industries Corporation Information
6.23.2 Taro Pharmaceutical Industries Semi-solid Dosage Description and Business Overview
6.23.3 Taro Pharmaceutical Industries Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Taro Pharmaceutical Industries Semi-solid Dosage Product Portfolio
6.23.5 Taro Pharmaceutical Industries Recent Developments/Updates
6.24 Teligent Pharma
6.24.1 Teligent Pharma Corporation Information
6.24.2 Teligent Pharma Semi-solid Dosage Description and Business Overview
6.24.3 Teligent Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Teligent Pharma Semi-solid Dosage Product Portfolio
6.24.5 Teligent Pharma Recent Developments/Updates
6.25 Perrigo Pharma
6.25.1 Perrigo Pharma Corporation Information
6.25.2 Perrigo Pharma Semi-solid Dosage Description and Business Overview
6.25.3 Perrigo Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Perrigo Pharma Semi-solid Dosage Product Portfolio
6.25.5 Perrigo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Semi-solid Dosage Industry Chain Analysis
7.2 Semi-solid Dosage Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Semi-solid Dosage Production Mode & Process
7.4 Semi-solid Dosage Sales and Marketing
7.4.1 Semi-solid Dosage Sales Channels
7.4.2 Semi-solid Dosage Distributors
7.5 Semi-solid Dosage Customers
8 Semi-solid Dosage Market Dynamics
8.1 Semi-solid Dosage Industry Trends
8.2 Semi-solid Dosage Market Drivers
8.3 Semi-solid Dosage Market Challenges
8.4 Semi-solid Dosage Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer